View Future GrowthPRF Technologies 과거 순이익 실적과거 기준 점검 0/6PRF Technologies 의 수입은 연평균 -11.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 8.7%의 비율로 증가했습니다. 매출은 연평균 105.5%의 비율로 증가해 왔습니다.핵심 정보-11.13%순이익 성장률80.65%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률105.50%자기자본이익률-54.06%순이익률-28,458.82%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesPRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical TrialApr 30Less than half of directors are independent Mar 12PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJan 21New major risk - Share price stability Jan 20PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract SurgeryJan 13PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJan 06Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery PlatformDec 11PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular TherapyDec 03PainReform Ltd., Annual General Meeting, Dec 30, 2025Nov 26PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisNov 13New major risk - Share price stability Aug 19New major risk - Revenue and earnings growth Apr 16PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd.Mar 07New minor risk - Financial data availability Mar 03PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million.Feb 19PainReform Ltd. Provides Further Update on Phase 3 Clinical Trial of PRF-110Dec 27Painreform Ltd. Announces CFO ChangesDec 06PainReform Ltd. Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNov 20PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNov 08PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $1.35 million.Oct 17PainReform Ltd., Annual General Meeting, Sep 30, 2024Aug 29PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAug 22painReform Ltd. Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyAug 20New major risk - Financial position Aug 18PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAug 13PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAug 08PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110Aug 06PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAug 02PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJul 25PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110Jun 26New major risk - Share price stability Jun 14PainReform Ltd. has completed a Follow-on Equity Offering in the amount of $7.999045 million.Apr 19Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110Apr 12PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApr 02PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $5 million.Mar 02New major risk - Shareholder dilution Jan 21Insufficient new directors Oct 01PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSep 13PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySep 08We're Keeping An Eye On PainReform's (NASDAQ:PRFX) Cash Burn RateJul 03New major risk - Revenue and earnings growth Jun 11PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryJun 08New major risk - Financial position Jun 08PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryMay 19PainReform Ltd., Annual General Meeting, Jun 08, 2023May 05PainReform Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price RequirementFeb 09PainReform Ltd., Annual General Meeting, Dec 29, 2022Nov 26Price target decreased to US$3.00 Nov 16PainReform Ltd. Provides Further Update on Manufacturing of PRF-110Nov 09PainReform Ltd. Provides PRF-110 Manufacturing UpdateOct 06PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationAug 17PainReform reports results Aug 16Price target decreased to US$3.00 Apr 27We're Hopeful That PainReform (NASDAQ:PRFX) Will Use Its Cash WiselySep 19Companies Like PainReform (NASDAQ:PRFX) Are In A Position To Invest In GrowthMay 23Forecast to breakeven in 2025 May 22PainReform Ltd. announced that it has received $5.999992 million in fundingMar 21Director has left the company Mar 10PainReform Ltd. announced that it expects to receive $5.999992 million in fundingMar 09PainReform Ltd. Announces Resignation of Assif Stoffman from Board of DirectorsMar 04New 90-day high: US$5.66 Feb 10PainReform Ltd. Appoints Rita Keynan as Vice President of Pharmaceutical OperationsJan 08New 90-day low: US$4.06 Jan 07PainReform Appoints Ilan Hadar as Chief Executive OfficerNov 24PainReform Ltd. Welcomes Ellen Baron as A Member of Board of DirectorsNov 14PainReform Ltd. Appoints Augustine Lawlor as Member of Board of DirectorsNov 10PainReform Ltd. has completed an IPO in the amount of $20 million.Sep 02매출 및 비용 세부 내역PRF Technologies가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:PRFX 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-53130 Sep 250-43130 Jun 250-43131 Mar 250-103731 Dec 240-1531230 Sep 240-1931430 Jun 240-1831531 Mar 240-133931 Dec 230-94630 Sep 230-84530 Jun 230-104631 Mar 230-94531 Dec 220-94430 Sep 220-74330 Jun 220-74331 Mar 220-74331 Dec 210-74330 Sep 210-74330 Jun 210-53231 Mar 210-52131 Dec 200-41030 Sep 200-41030 Jun 200-41031 Mar 200-41031 Dec 190-21030 Sep 190-20030 Jun 190-20031 Mar 190-20031 Dec 180-200양질의 수익: PRFX 은(는) 현재 수익성이 없습니다.이익 마진 증가: PRFX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PRFX은 수익성이 없으며 지난 5년 동안 손실이 연평균 11.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PRFX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PRFX은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-3.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PRFX는 현재 수익성이 없으므로 자본 수익률이 음수(-54.06%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 07:07종가2026/05/04 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PRF Technologies Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jason McCarthyMaxim GroupNazibur RahmanMaxim Group
PRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical TrialApr 30
PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJan 21
PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract SurgeryJan 13
PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJan 06
Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery PlatformDec 11
PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular TherapyDec 03
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisNov 13
PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd.Mar 07
PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million.Feb 19
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNov 08
PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAug 22
PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAug 13
PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAug 08
PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAug 02
PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJul 25
PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110Jun 26
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110Apr 12
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApr 02
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSep 13
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySep 08
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryJun 08
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryMay 19